EP006

EP006 is a biological drug candidate developed by Endpoint Health. It acts as an activator of antithrombin III (AT III), a key serine protease inhibitor involved in the regulation of blood coagulation. By activating AT III, EP006 is designed to modulate coagulation pathways, potentially providing therapeutic benefit in conditions characterized by dysregulated clotting and inflammation. The primary indication under investigation for EP006 is sepsis, a severe and life-threatening response to infection that can lead to disseminated intravascular coagulation and organ failure. As of March 2025, the highest reported development status for EP006 is preclinical[1].